Duke Cancer Network

#DukeDebates2024 @SusanBal9 Anti-CD38-based quadruplet therapy is considered standard of care for induction therapy for high risk MM but the optimal regimen is unknown.

#DukeDebates2024 Raymond Thertulien, MD, PhD Anti-CD38-based quadruplet therapy is considered standard of care for induction therapy for high risk MM patients

#DukeDebates2024 APP Session Jill Barbour, MSN, MA, WHNP-BC "Sex is one more thing that cancer stole from me." "Forty-three percent of cancer survivors ranked sex as one of their top concerns."

Highlight from #DukeDebates2024 Nicolas Short MD Triplet combinations with HMA+ven+a FLT3 or IDH1/2 inhibitor achieve high rates of response and durable remissions in newly diagnosed AML #DukeCancer

@DukeDebates24 Kami Maddocks MD Autologous CD19 directed CAR-T cell therapies have shown survival benefit in 2nd line setting for pts w/ refractory large B cell lymphoma. 3 autologous CD19 directed CAR-T cell therapies are approved in 3rd or later line and 2 in 2nd line setting.

@DukeDebates2024 Alexandra Stefanovic MD debates Novel agents deserve a role in first-line treatment of early-stage Hodgkin lymphoma. @DukeHealth @DukeCancer

@DukeDebates2024 Chris Kelsey MD “Despite new and exciting drugs, the classic regimen of ABVD X 2 + two weeks of radiation therapy is still the standard in early-stage, favorable, Hodgkin lymphoma.” @DukeHealth

@DukeDebates2024 Chris Kelsey MD states "Nivolumab might become an important modality in early-stage Hodgkin lymphoma….but confirmatory phase III trials needed.” @DukeHealth

@DukeDebates2024 @Danilovlab discusses non-covalent BTK inhibitor pirtobrutinib, as a drug of choice in ibrutinib-resistant patients due to high efficacy and safety, with BTK degraders as a new emerging tool to further address resistance to BTK inhibitors @DukeHealth

@DukeDebates24 Harry Erba MD & Danielle Brander MD kick off 24th Annual Duke Debates: Controversies in the Management of Hematologic Malignancies in Hilton Head SC @DukeHealth

Thank you to Co-Directors Drs Linda Sutton, Trey Blazer, Christine Eyler, all presenters and attendees. Duke Cancer Review 2023 was FANTASTIC! See you next yr, July 2024 at the Umstead, Cary NC @dukecancerntwk @dukecancer

Advances in GI Ca by DCR co-director Dr. Christine Eyler, & Drs Neeraj Agrawal, Julie Thacker & David Hsu. Dr. Hsu-Rectal Ca-tx for locally advanced disease evolving; Multidisplinary eval needed @dukecancerNTWK @DukeCancer

Dr. Maggie Dinome"Early data from TAXIS study support that ALND didn't change adjuvant systemic tx recommendations in pts with node+ breast ca, "Surgical management of lymph node positive breast cancer continues toward de-escalation for pts w/ ER+Her2 - disease"@dukecancerntwk

Dr. Alice Ho “Multiple strategies for reducing radiation dose to the heart exist for L-sided breast ca pts w/ challenging anatomies, such as deep-inspiratory breast hold, intensity modulated radiotherapy and proton therapy” @DukeCancerNTWK @dukecancer

All about breast ca: Dr. Rani Bansal · Abemaciclib curr-ently the only FDA approved adjuvant therapy in HR+ HER2- breast ca for CDK4/6i. NATALEE trial- absolute distant-disease free survival benefit of 2.2%@2yrs ET+ ribociclibvsET alone.@dukecancerntwk @dukecancer

Excellent presentation by Dr. Larrier, bringing attention to "Radiation dose for sarcoma- how low can we go?" @DukeCancer @DukeCancerNTWK @alanalperMD

Dr. Grilley Olson highlights-While adjuvant chemotherapy for soft tissue sarcomas remains controversial, many new and often histology tailored chemotherapies have emerged in the recurrent/metastatic setting. @DukeCancer @DukeCancerNTWK @AlanAlperMD

From Dr. Grilley Olson-Within the Duke Cancer Center, the Duke Sarcoma Center is designated as a center of excellence with a robust multidisciplinary team For sarcoma clinical trials, contact the sarcoma research team at 919-681-6807 @DukeCancer @DukeCancerNETWK @AlanAlperMD .

@AlanAlperMD - IR options are included in the NCCN guidelines for Sarcoma, Adult Cancer Pain, and Palliative Care IR is a tx option for even chemoradiotherapy-resistant and surgically recurrent tumors, with curative or palliative intent @DukeCancer @DukeCancerNTWK

Duke Cancer Review day 2 is off to a phenominal start. Thank you SARCOMA presenters Drs Hui Chen, Juneko Grilley-Olson, Nicole Larrier, Julia Visgauss, & Alan Sag for getting the cancer care energy flowing!@CancerCare @sarcomacancer ca @DukeCancerNTWK @AlanAlperMD